Safety Evaluation of 700 cases of Danhong Injection in Its Clinical Application by Active Centralized Monitoring

Abstract

Abstract: Objective To evaluate the clinical safety of the Danhong injection． MethodsMedication and Patient data and ADR of 700 cases of Danhong Injection in our hospital were collected by active centralized minitoring during the period of January and October 2011． ResultsBased on the 700 inpatient cases which involved 8 departments and 16 rinds of diseases, whilst ADR occurred in 3 cases(0.43% of the total). 73.71% of the injection-takers were old patierits, 105 cases of the medication is unreasonable, accounting for 15.00％． Condusion A low incidence of ADR for the Danhong injection in its clinical application was found. Irrational drug use can increase safety risk. We should strengthen the supervision of clinical rational use of traditional Chinese medicine injections．

Key words: Danhong injection, safety, active centralized monitoring

KANG A-long, ZHANG Xian, HUANG Li-ming, SUN Cheng-rong, MAI Jin-qiang. Safety Evaluation of 700 cases of Danhong Injection in Its Clinical Application by Active Centralized Monitoring[J]. Chinese Journal of Pharmacovigilance, 2012, 9(6): 360-362.

[1]	JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui. Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
[2]	MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
[3]	BAI Zhaofang, ZHAN Xiaoyan, YAO Qing, CHEN Simin, ZHAO Xu, XIAO Xiaohe. Theoretical innovation and technological breakthroughs in the safety evaluation of traditional Chinese medicine: disease-syndrome-based toxicology [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 6-14.
[4]	FANG Zhie, LI Chengxian, BAI Zhaofang, ZHAO Xu, WANG Jiabo, XIAO Xiaohe. Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 20-24.
[5]	XIONG Weiyi, REN Jingtian. Considerations for revision of safety information in package inserts of anti-cancer drugs in post-market phase [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 94-97.
[6]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[7]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[8]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[9]	SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
[10]	YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin. Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
[11]	LIU Qian, HU Jing, LI Bo, YANG Xiaojing. Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
[12]	YU Hongli, YU Dongmei, XIAO Aili, ZHU Lan, SONG Haibo. Risks of safety Qingkailing oral preparation [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1046-1048.
[13]	LI Jing, XU Ye, LIU Ranjia, PAN Chen, CUI Xiangli. Adverse reactions in patients with COVID-19 after using tocilizumab [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1049-1053.
[14]	LI Yamei, SHUI Rong. Research progress in tofacitinib for juvenile idiopathic arthritis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 956-960.
[15]	WANG Rong, LIU Ziqun, WANG Nana, TAN Xiong, ZHANG Yixin, YANG Kuan, QIN Bei. Acute toxicity of proline Danshensu borneol ester in mice [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 754-757.

Safety Evaluation of 700 cases of Danhong Injection in Its Clinical Application by Active Centralized Monitoring

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics